From BILAG to BLIPS--disease activity assessment in lupus past, present and future.
about
Belimumab for systemic lupus erythematosusHerbal medicines for systemic lupus erythematosusB-cell survival factors in autoimmune rheumatic disordersMeasuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical researchFrom BILAG to BILAG-based combined lupus assessment-30 years onA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusLipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosusBaseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusAnti-DNA antibodies--overview of assays and clinical correlations.Clinical laboratory assays for measuring anti-dsDNA antibodies. Where are we now?Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease.Prevalence and predictors of fragility fractures in systemic lupus erythematosus.Clinical trial design in systemic lupus erythematosus: lessons learned and future directions.Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosusBelimumab (benlysta): a breakthrough therapy for systemic lupus erythematosus.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow TransplantationEffects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsNovel evidence-based systemic lupus erythematosus responder index.A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.European consensus statement on the terminology used in the management of lupus glomerulonephritis.Numerical scoring for the Classic BILAG indexEpratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.Sirukumab : a novel therapy for lupus nephritis?The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus.Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years.Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.Impaired endothelial function in systemic lupus erythematosus.
P2860
Q24201547-A1517559-80E0-42D5-91EE-71879FEACBCDQ24246699-D3D038B3-EE76-49FA-92F7-19E6D2AC5A70Q26796484-2CB31367-E8E2-499C-88DE-4E7D770FDF16Q26799223-802B90D1-D541-466C-AFC3-BB2D2E5A1250Q28081809-FD890147-FFC2-48F9-8537-9C1D00FA29D6Q28254310-8F5BA091-F17A-417E-B016-84067CE540E0Q30588683-CBD5DD94-6BF2-4E2A-B467-51589149C2C6Q30645037-C8D262B8-699D-483A-B235-26B5F0320744Q30832522-2DCAC0B3-C99D-4D16-8979-DFF1DF4A8A86Q34267149-F0E1D6FB-6DA4-4F30-AE30-8E3A14C33702Q34897437-DBDC8C55-366A-44E6-B0B0-7BB2BE3809E9Q35045844-7F9B068D-1247-4339-94FD-AC67F46A2B17Q35045883-DA2DE154-6C96-4701-A11D-FCC095B6FF9FQ35310520-639F8A09-1060-457C-A66A-99E25FB41996Q35554619-451D77AF-93B2-4565-8AB7-81775020F08DQ35824541-B6BE92C2-F7D0-403F-9F5A-416176F31391Q35954719-E4D0E95B-0B50-438F-96BE-9558ED01CE97Q35958642-8E2A6883-89B8-4605-93F8-B46B28EC3A2BQ35993027-14F3B3A1-D102-424B-8BE7-1DA06FB38703Q36020897-7F794699-D9CD-40BB-95B8-32D3551FB96BQ36302240-2AEACD03-B617-4456-8DE7-2FCBD932C089Q37356378-BE25BFA7-8BC3-4291-839C-4F373C12CCB6Q37378350-BC99252A-D00E-4AC1-8271-CA6A73D8BC6AQ37391863-30D02D1E-63D7-4F7C-82DB-91A5EC1C53DCQ37421244-D59AB155-C110-4D2F-B86E-7A20C73CA6C9Q37595993-57B9A071-FBF1-4099-A910-F2397AB73C77Q37809939-3F256F2D-465D-456B-A529-E8A2EB2E94A5Q38086135-0106BED5-2D46-4077-8C56-680FDE0B9A44Q38246130-6B206E3E-8E44-4E1B-AF5D-15E4C75BB1E2Q38309470-C4D27B0D-7551-4872-8DED-18AA222AFFFCQ40621351-6A7B2DD4-347D-4C13-BB2C-5C840B4FC0ABQ41698087-67FF5817-422B-4DCB-B281-906053AF022DQ42638034-16D852FD-D8DA-44D9-85C0-830FB46150D5Q42694406-E5DECBE0-CA38-497D-B21B-3BC057F45C82Q43234058-94D7DEAE-84B7-478C-9FE6-1BE7F0FDBAEBQ45821336-90B25BC7-01DE-44F4-B06E-98C6E9F80558Q51758271-2EF8DC2A-ADF8-4CBF-8FDA-431B9DA06CA5
P2860
From BILAG to BLIPS--disease activity assessment in lupus past, present and future.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
From BILAG to BLIPS--disease activity assessment in lupus past, present and future.
@en
type
label
From BILAG to BLIPS--disease activity assessment in lupus past, present and future.
@en
prefLabel
From BILAG to BLIPS--disease activity assessment in lupus past, present and future.
@en
P2860
P1433
P1476
From BILAG to BLIPS--disease activity assessment in lupus past, present and future.
@en
P2093
BILAG Group. British Isles Lupus Assessment Group
P2860
P304
P356
10.1191/096120300672904669
P577
2000-01-01T00:00:00Z